163 related articles for article (PubMed ID: 30409253)
1. PET Molecular Imaging in Familial Parkinson's Disease.
Matarazzo M; Wile D; Mackenzie M; Stoessl AJ
Int Rev Neurobiol; 2018; 142():177-223. PubMed ID: 30409253
[TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.
de Natale ER; Niccolini F; Wilson H; Politis M
Int Rev Neurobiol; 2018; 141():131-172. PubMed ID: 30314595
[TBL] [Abstract][Full Text] [Related]
3. SPECT Molecular Imaging in Familial Parkinson's Disease.
Varrone A; Pellecchia MT
Int Rev Neurobiol; 2018; 142():225-260. PubMed ID: 30409254
[TBL] [Abstract][Full Text] [Related]
4. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
[TBL] [Abstract][Full Text] [Related]
5. Molecular Imaging of Neuroinflammation in Idiopathic Parkinson's Disease.
Roussakis AA; Piccini P
Int Rev Neurobiol; 2018; 141():347-363. PubMed ID: 30314603
[TBL] [Abstract][Full Text] [Related]
6. Molecular Imaging of the Cannabinoid System in Idiopathic Parkinson's Disease.
Cilia R
Int Rev Neurobiol; 2018; 141():305-345. PubMed ID: 30314601
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson's disease.
Varrone A; Svenningsson P; Forsberg A; Varnäs K; Tiger M; Nakao R; Halldin C; Nilsson LG; Farde L
Neurobiol Aging; 2014 Apr; 35(4):867-75. PubMed ID: 24126162
[TBL] [Abstract][Full Text] [Related]
8. Molecular Imaging of the Serotonergic System in Parkinson's Disease.
Pagano G; Politis M
Int Rev Neurobiol; 2018; 141():173-210. PubMed ID: 30314596
[TBL] [Abstract][Full Text] [Related]
9. Update on Molecular Imaging in Parkinson's Disease.
Liu ZY; Liu FT; Zuo CT; Koprich JB; Wang J
Neurosci Bull; 2018 Apr; 34(2):330-340. PubMed ID: 29282614
[TBL] [Abstract][Full Text] [Related]
10. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
[TBL] [Abstract][Full Text] [Related]
11. PET imaging in neurology: Alzheimer's and Parkinson's diseases.
Sarikaya I
Nucl Med Commun; 2015 Aug; 36(8):775-81. PubMed ID: 25920047
[TBL] [Abstract][Full Text] [Related]
12. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
13. Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease.
Nahimi A; Kinnerup MB; Sommerauer M; Gjedde A; Borghammer P
Int Rev Neurobiol; 2018; 141():251-274. PubMed ID: 30314598
[TBL] [Abstract][Full Text] [Related]
14. SPECT molecular imaging in Parkinson's disease.
Wang L; Zhang Q; Li H; Zhang H
J Biomed Biotechnol; 2012; 2012():412486. PubMed ID: 22529704
[TBL] [Abstract][Full Text] [Related]
15. Imaging the Nonmotor Symptoms in Parkinson's Disease.
Yousaf T; Wilson H; Politis M
Int Rev Neurobiol; 2017; 133():179-257. PubMed ID: 28802921
[TBL] [Abstract][Full Text] [Related]
16. Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease.
Ghadery C; Valli M; Mihaescu A; Strafella R; Navalpotro I; Kim J; Strafella AP
Int Rev Neurobiol; 2018; 141():365-404. PubMed ID: 30314604
[TBL] [Abstract][Full Text] [Related]
17. PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.
Pagano G; Yousaf T; Politis M
Curr Neurol Neurosci Rep; 2017 Oct; 17(11):90. PubMed ID: 28975571
[TBL] [Abstract][Full Text] [Related]
18. Molecular Imaging of Opioid System in Idiopathic Parkinson's Disease.
Thobois S; Brefel-Courbon C; Le Bars D; Sgambato-Faure V
Int Rev Neurobiol; 2018; 141():275-303. PubMed ID: 30314599
[TBL] [Abstract][Full Text] [Related]
19. Abnormal metabolic brain network associated with Parkinson's disease: replication on a new European sample.
Tomše P; Jensterle L; Grmek M; Zaletel K; Pirtošek Z; Dhawan V; Peng S; Eidelberg D; Ma Y; Trošt M
Neuroradiology; 2017 May; 59(5):507-515. PubMed ID: 28386687
[TBL] [Abstract][Full Text] [Related]
20. Imaging beyond the striatonigral dopaminergic system in Parkinson's disease.
Giza E; Gotzamani-Psarrakou A; Bostantjopoulou S
Hell J Nucl Med; 2012; 15(3):224-32. PubMed ID: 23106055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
